<DOC>
	<DOCNO>NCT02443688</DOCNO>
	<brief_summary>This study Phase 2 , double-blind , randomize , placebo-controlled study evaluate safety efficacy CTX-4430 administer once-daily 48 week treatment CF .</brief_summary>
	<brief_title>EMPIRE CF : A Phase 2 Study Evaluate Efficacy , Safety , Tolerability CTX-4430 Adult CF Patients</brief_title>
	<detailed_description>This study Phase 2 , double-blind , randomize , placebo-controlled study evaluate safety efficacy CTX-4430 administer once-daily 48 week treatment CF . A total 195 pulmonary CF patient meet inclusion exclusion criterion provide write informed consent randomize receive 50 mg CTX-4430 , 100 mg CTX-4430 , placebo 1:1:1 ratio . Follow-up visit conduct approximately every 4 week Week 4 Week 52 ( 4 week completion treatment ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>FEV1 â‰¥50 percent predict Screening At least 1 pulmonary exacerbation 12 month Screening Pregnant nursing woman Medical condition unstable , could adversely impact participation study , could impact assessment study result History organ transplantation History alcoholism drug abuse within 2 year Screening Regular use highdose NSAID within 60 day Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>